CD6-Directed Immunotherapy Targets Breast Cancer Stem Cell Function and Enhances Immune-Mediated Cytotoxicity in Triple-Negative Breast Cancer
Biomolecules · 17.08.2026 · 16 (8) · 1202
DOI: 10.3390/biom16081202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 17.08.2026. Verfasst von Mikel Gurrea-Rubio und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neoplastic Stem Cells, Immunotherapy, Antigens, CD. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIH HHS, NIH.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is associated with recurrence, metastasis, and limited durable responses to immunotherapy, in part due to persistence of breast cancer stem cells (BCSCs). We investigated whether CD6-directed immunotherapy with the monoclonal antibody UMCD6 enhances immune-mediated killing and alters function of BCSC in stem cell-enriched TNBC models. The SUM-149 and SUM-159 cell lines were analyzed for CD6 ligand expression, cocultured with human peripheral blood mononuclear cells (PBMCs) treated with UMCD6, pembrolizumab, or isotype control, and assessed by live-cell cytotoxicity imaging, flow cytometry, soft agar colony formation, and extreme limiting dilution sphere assays. Both TNBC lines co-expressed the CD6 ligands CD44, CD166/ALCAM, and CD318/CDCP1. UMCD6 significantly increased PBMC-mediated apoptosis and reduced tumor cell survival in both models, with greater activity than pembrolizumab under these in vitro conditions. In surviving SUM-159 cells, UMCD6 reduced the ALDH+ population wit×hout significantly altering CD44+CD24− frequency, indicating preferential effects on a distinct stem-like compartment. Functionally, UMCD6 decreased anchorage-independent colony formation and reduced sphere-forming frequency from 1/33.6 to 1/68.3 cells (p = 0.0186). These findings identify the CD6 ligand axis as a therapeutic vulnerability in BCSC-enriched TNBC and support further preclinical evaluation of CD6-directed immunotherapy as a strategy to enhance antitumor immunity while limiting tumor-initiating capacity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
ORCID-Profile: Mikel Gurrea-Rubio, Aditya Chada, Pei-Suen Tsou, Laura A Cooney, David A Fox
Förderung
- NCATS NIH HHS
- NIH HHS
- NIH
- University of Michigan
Zitieren
APA
Gurrea-Rubio, M., Sloan, S., Chada, A., Amarista, C. I., Maeda, K., Campbell, P. L., Tsou, P. S., Cooney, L. A., Wicha, M. S., & Fox, D. A. (2026). CD6-Directed Immunotherapy Targets Breast Cancer Stem Cell Function and Enhances Immune-Mediated Cytotoxicity in Triple-Negative Breast Cancer. Biomolecules, 16(8), 1202. https://doi.org/10.3390/biom16081202
Vancouver
Gurrea-Rubio M, Sloan S, Chada A, Amarista CI, Maeda K, Campbell PL, et al. CD6-Directed Immunotherapy Targets Breast Cancer Stem Cell Function and Enhances Immune-Mediated Cytotoxicity in Triple-Negative Breast Cancer. Biomolecules. 2026;16(8):1202. doi:10.3390/biom16081202
BibTeX
@article{GurreaRubio2026,
author = {Gurrea-Rubio, Mikel and Sloan, Sophie and Chada, Aditya and Amarista, Camila I and Maeda, Kohei and Campbell, Phillip L and Tsou, Pei-Suen and Cooney, Laura A and Wicha, Max S and Fox, David A},
title = {CD6-Directed Immunotherapy Targets Breast Cancer Stem Cell Function and Enhances Immune-Mediated Cytotoxicity in Triple-Negative Breast Cancer},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {8},
pages = {1202},
doi = {10.3390/biom16081202}
}
EUVIMED